Circulating biomarkers in hepatocellular carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 2, 2014, Pages 323-332

  Morris, Karen L ^a   Tugwood, Jonathan D ^a   Khoja, Leila ^a   Lancashire, Matthew ^a   Sloane, Robert ^a   Burt, Debbie ^a   Shenjere, Patrick ^c   Zhou, Cong ^a   Hodgson, Clare ^a   Ohtomo, Toshihiko ^b   Katoh, Atsuhiko ^b   Ishiguro, Takahiro ^b   Valle, Juan W ^c   Dive, Caroline ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Circulating tumour cells (CTCs); Cytokeratin 18 (CK18); Glypican 3 (GPC3); Hepatocellular carcinoma (HCC); Prognostic biomarker

Indexed keywords

BIOLOGICAL MARKER; CASPASE; CYTOKERATIN 18; GLYPICAN 3;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL COUNT; CHILD PUGH SCORE; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL SEPARATION; FEMALE; FOLLOW-UP STUDIES; GLYPICANS; HUMANS; IMMUNOENZYME TECHNIQUES; KERATIN-18; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907597215     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2508-7     Document Type: Article

References (30)

1. Maluccio M, Covey A (2012) Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62(6):394-399
2. Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an ASLD single topic conference. Hepatology 37(5):1202-1219 (Pubitemid 36538699)
3. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y (2003) Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306(1):16-25 (Pubitemid 36629398)
4. Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P, Paradis V (2006) Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 37(11):1435-1441 (Pubitemid 44739946)
5. Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA (2013) First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 19(4):920-928
6. Hou J-M, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall F (2009) Evaluation of circulating tumour cells and serological death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 175:808-816
7. Krebs MG, Sloane R, Priest L, Lancashire L, Hou J-M, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non small-cell lung cancer. J Clin Oncol 29(12):1556-1563
8. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Brechot C, Paterlini-Brechot P (2000) Isolation by size of epithelial tumour cells: a new method for the immunomorphological and molecular characterisation of circulating tumour cells. Am J Pathol 156:57-63 (Pubitemid 30644439)
9. Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, Sugo I, Ohizumi I, Aburatani H, Hamakubo T, Kodama T, Tsuchiya M, Yamada-Okabe H (2008) Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 68(23):9832-9838
10. Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, Kodama T, Aburatani H, Yamada-Okabe H, Tsuchiya M (2009) Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun 378(2):279-284
11. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AGJ, Uhr JW, Terstappen LWMM (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10(20):6897-6904 (Pubitemid 39383039)
12. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cell search system. Clin Cancer Res 13(3):920-928 (Pubitemid 46340368)
13. Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, Hughes A, Blackhall F, Valle JW, Dive C (2012) A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer 106(3):508-516
14. Cummings J, Ward T, LaCasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M, Dive C (2005) Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 92:532-538 (Pubitemid 40395534)
15. Cummings J, Ranson M, LaCasse E, Gangangari J, St-Jean M, Jayson G, Durkin J, Dive C (2006) Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 95:42-48 (Pubitemid 43980552)
16. Gao P, Jiao S-C, Bai L, Wang H, Jing F-F, Yang J-L (2013) Detection of circulating tumour cells in gastric and hepatocellular carcinoma: a systematic review. J Int Med Res 41(4):923-933
17. Went PTH, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35(1):122-128 (Pubitemid 38133932)
18. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136(3):1012-1024
19. Sun Y-F, Xu Y, Yang X-R, Guo W, Zhang X, Qiu S-J, Shi R-Y, Hu B, Zhou J, Fan J (2013) Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 57(4):1458-1468
20. Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H (2013) Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 133(9):1365-1371
21. Vona G, Estepa L, Béroud C, Damotte D, Capron F, Nalpas B, Mineur A, Franco D, Lacour B, Pol S, Bréchot C, Paterlini-Bréchot P (2004) Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 39(3):792-797 (Pubitemid 38337659)
22. Pantel K, Alix-Panabières C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16(9):398-406
23. Zhang YLJ, Cao L, Xu W, Zhengfeng Yin (2012) Circulating tumour cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol 39:449-460
24. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C (2008) Biomarker method validation in anticancer drug development. Br J Pharmacol 153(4):646-656 (Pubitemid 351271750)
25. Greystoke A, Dean E, Saunders MP, Cummings J, Hughes A, Ranson M, Dive C, Renehan AG (2012) Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. Br J Cancer 107(9):1518-1524
26. Oyama K, Fushida S, Kinoshita J, Okamoto K, Makino I, Nakamura K, Hayashi H, Inokuchi M, Nakagawara H, Tajima H, Fujita H, Takamura H, Ninomiya I, Kitagawa H, Fujimura T, Ohta T (2012) Serum cytokeratin 18 as a biomarker for gastric cancer. Clin Exp Med 13(4):289-295
27. Yildiz I, Sen F, Kilic L, Keskin S, Duranyildiz D, Bilgin E, Disci R, Ekenel M, Darendeliler E, Bavbek S, Basaran M (2013) Serum M65 as a biomarker for metastatic renal cell carcinoma. Clin Genitourin Cancer 11(3):290-296
28. Waidmann O, Köberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiss M, Kronenberger B, Piiper A (2013) Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. J Hepatol 59(4):769-779
29. Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, Wedemeyer I, Marquitan G, Gieseler RK, Baba HA, Gerken G, Canbay A (2010) Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology 51(1):92-102
30. Maliken B, Nelson JE, Klintworth HM, Beauchamp M, Yeh MM, Kowdley KV (2013) Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology 57(5):1806-1813